Comparison · NCT01568866-sae
Bortezomib vs Carfilzomib: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Bortezomib vs Carfilzomib: serious adverse events. Trial comparisons, record NCT01568866-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01568866-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.399 | 0.355 | 0.445 | wilson | |
| Risk in group 2 | 0.587 | 0.542 | 0.631 | wilson | |
| Risk difference, group 1 minus group 2 | -0.188 | -0.25 | -0.124 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.679 | 0.593 | 0.778 | log | |
| Odds ratio, group 1 over group 2 | 0.466 | 0.358 | 0.607 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Bortezomib than on Carfilzomib | 5.31 | 3.99 | 8.06 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Bortezomib | 182 | 456 | EG000 | |
| Group 2 | Carfilzomib | 272 | 463 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
From the first dose of study drug up to 30 days after the last dose of study drug as of the data cut-off date of 03 January 2017; median duration of treatment was 27 weeks in the bortezomib group and 48 weeks in the carfilzomib treatment group.
Source ClinicalTrials.gov
Trial
- Title
- Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
- NCT number
- NCT01568866
- Phases
- PHASE3
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Bortezomib, Dexamethasone
- Lead sponsor
- Amgen
- Results first posted
- 2015-12-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01568866?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01568866-sae